电子邮件 | bsh***@***.com | 获取Email |
---|
电子邮件 | bsh***@***.com | 获取Email |
---|
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today's targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango's programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango's success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
公司 | Tango Therapeutics |
---|---|
职位 | Senior Principal Scientist |
地点 | United States |
http://www.linkedin.com/in/binzhang-shen-55895b58 | |
部门 | master_engineering_technical |
头衔 | Molecular Biology |
Tango Therapeutics Senior Principal Scientist
2020-06-01 -
Cogent Biosciences Senior Scientist
2019-03-01 - 2020-03-01
Agrivida, Inc. Senior Scientist
2007-11-01 - 2019-03-01
Harvard Medical School Postdoctoral Researcher Fellow
2001-08-01 - 2007-10-01
Rutgers University–New Brunswick Graduate Research Assistant
1996-09-01 - 2001-07-01
Binzhang Shen 在 Tango Therapeutics 担任 Molecular Biology
Binzhang Shen 在 Tango Therapeutics 的职位是 Molecular Biology
Binzhang Shen 的电子邮件地址是 bsh***@***.com
Binzhang Shen 的电话号码是 -
Binzhang Shen 的公司电话号码是 +185****
Binzhang Shen 在 research 工作。
Binzhang Shen 的一些同事包括Binzhang Shen、Colin Liang、Amanda Galgay、Jon ComeJade Green、。
Binzhang Shen联系方式: 电子邮件地址:bsh***@***.com 电话号码:-
Binzhang Shen 的个人领英是:http://www.linkedin.com/in/binzhang-shen-55895b58
Binzhang Shen 的办公地点:100 binney st, boston, massachusetts, united states
全球B2B企业库
海关贸易数据
展销采购数据
Top-ranked on G2 Crowd